Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud, Ciudad de México, México; Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, México.
Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud, Ciudad de México, México; Tecnológico Nacional de México, Tecnológico de Estudios Superiores de Huixquilucan, México.
Life Sci. 2024 Oct 15;355:123015. doi: 10.1016/j.lfs.2024.123015. Epub 2024 Aug 23.
Cancer Stem Cells (CSCs) are highly tumorigenic, chemoresistant, and immune evasive. They emerge as a central driver that gives rise to the bulk of tumoral mass, modifies the tumor microenvironment (TME), and exploits it, leading to poor clinical outcomes for patients with cancer. The existence of CSCs thus accounts for the failure of conventional therapies and immune surveillance. Identifying CSCs in solid tumors remains a significant challenge in modern oncology, with the use of cell surface markers being the primary strategy for studying, isolating, and enriching these cells. In this review, we explore CSC markers, focusing on the underlying signaling pathways that drive CSC self-renewal, which simultaneously makes them intrinsically chemoresistant and immune system evaders. We comprehensively discuss the autonomous and non-autonomous functions of CSCs, with particular emphasis on their interactions with the tumor microenvironment, especially immune cells. This reciprocal network enhances CSCs malignancy while compromising the surrounding niche, ultimately defining therapeutic vulnerabilities associated with each CSC marker. The most common CSCs surface markers addressed in this review-CD44, CD133, ICAM1/CD54, and LGR5-provide insights into the interplay between chemoresistance and immune evasion, two critically important phenomena in disease eradication. This new perspective on the state-of-the-art of CSCs will undoubtedly open new avenues for therapy.
癌症干细胞 (CSCs) 具有高度致瘤性、耐药性和免疫逃避性。它们是导致肿瘤大量出现的核心驱动因素,改变肿瘤微环境 (TME) 并加以利用,导致癌症患者的临床预后不佳。因此,CSCs 的存在解释了常规疗法和免疫监测的失败。在现代肿瘤学中,识别实体瘤中的 CSCs 仍然是一个重大挑战,使用细胞表面标志物是研究、分离和富集这些细胞的主要策略。在这篇综述中,我们探讨了 CSC 标志物,重点关注驱动 CSC 自我更新的潜在信号通路,这同时使它们具有内在的耐药性和免疫系统逃避性。我们全面讨论了 CSCs 的自主和非自主功能,特别强调它们与肿瘤微环境(尤其是免疫细胞)的相互作用。这种互惠网络增强了 CSCs 的恶性程度,同时损害了周围的生态位,最终确定了与每个 CSC 标志物相关的治疗弱点。本综述中讨论的最常见的 CSCs 表面标志物-CD44、CD133、ICAM1/CD54 和 LGR5-深入探讨了耐药性和免疫逃避之间的相互作用,这是疾病根除中两个非常重要的现象。对 CSCs 最新进展的这种新观点无疑将为治疗开辟新途径。